Algipharma

Focus: Algipharma is a Norwegian biotech company focused on small molecule oligosaccharide therapeutics for respiratory and rare disease indications, particularly cystic fibrosis and COPD. The company operates at the clinical stage with a focused pipeline and public market status.

Respiratory Rare Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Algipharma

AI assessmentNot Hiring

No open roles listed right now. Follow Algipharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OligoG CF-5/20

Cystic Fibrosis

Phase 1

Clinical Trials (1)

NCT00970346Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

Phase 1

Help build intelligence for Algipharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need respiratory indications (CF, COPD) with 7 active trials providing clear development trajectory
Rare disease and orphan indication focus offers potential for accelerated pathways and specialized scientific work
Public company status provides stability and access to capital markets absent in private biotech

Watch Out For

Zero active job openings signal potential hiring freeze or organizational stasis, limiting entry opportunities
No approved products or revenue means company is entirely dependent on pipeline success with no commercial diversification
Limited public data on financials, headcount, and R&D spending raises transparency concerns and makes career growth forecasting difficult

Generated by Claude from Algipharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

OligoG CF-5/20

Cystic Fibrosis

Phase 1/2

Clinical Trials (1)

NCT01465529A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

Phase 1/2

Radiolabelled OligoG CF-5/20 DPI

Cystic Fibrosis

Phase 2

Clinical Trials (1)

NCT01991028A Study to Investigate Lung Deposition of Radiolabelled OligoG

Phase 2

OligoG DPI

Cystic Fibrosis

Phase 2

Clinical Trials (1)

NCT03822455A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

Phase 2

alginate oligosaccharide

Cystic Fibrosis

Phase 2/3

Clinical Trials (2)

NCT02453789A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

Phase 2

NCT02157922A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

Phase 2

OligoG Dry powder for inhalation

Cystic Fibrosis

Phase 2/3

Clinical Trials (1)

NCT03698448A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2012

Portfolio: 7 clinical trials

Top TAs: Rare Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Rare Diseases

7 pipeline

Marketed

Pipeline